Invasive NSTEMI Strategy Shows No Benefit in Frail Patients - Summary - MDSpire
From the Journals

Invasive NSTEMI Strategy Shows No Benefit in Frail Patients

Frailty severity may identify older patients least likely to benefit—and potentially at higher risk—with invasive management

  • By

  • Kathryn Wighton

  • May 6, 2026

  • 4 min

Share

In a comprehensive analysis of the SENIOR-RITA randomized clinical trial, researchers examined the efficacy of routine invasive strategies versus conservative management in frail patients aged 75 and older with non–ST-elevation myocardial infarction. Among the 1,446 evaluated patients, those following invasive management exhibited higher rates of cardiovascular death and nonfatal myocardial infarction compared to conservative management, particularly at higher levels of frailty. Notably, the invasive strategy failed to demonstrate significant benefits, suggesting potential harm among the frailest individuals. Lead researcher Francesca Rubino, MD, emphasizes the need for careful evaluation of treatment approaches in this vulnerable population.

Original Source(s)

Invasive NSTEMI Strategy Shows No Benefit in Frail Patients

  • by Kathryn Wighton

  • May 6, 2026

Related Content

Cardiovascular Effects and Risk Factors Identified With BRAF and MEK Inhibition in Melanoma

A cohort study showed that patients with melanoma who received BRAF or MEK inhibitor therapy commonly experienced hypertension and mild cardiac dysfunction, supporting baseline cardiotoxicity risk str...

Most Decline Proactive Care Coordination

"Lack of effective communication across physicians is a health system problem."

Bereavement Tied to Higher Cardiovascular Risk

Acute post-loss period and pandemic conditions each amplified cardiovascular vulnerability in nationwide Swedish cohort study